To include your compound in the COVID-19 Resource Center, submit it here.

Kala reports mixed Phase III data for dry eye candidate KPI-121

Kala Pharmaceuticals Inc. (NASDAQ:KALA) reported top-line data from the Phase III STRIDE 1 and STRIDE 2 trials of KPI-121 0.25% to treat signs and symptoms of dry eye disease. The candidate is

Read the full 329 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE